Programmed cell death protein 1 (PD-1) inhibitors also showed activity against BMs from non-small-cell lung cancer (NSCLC) with PD-L1 ≥ 50% (Metro et al. 2020). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.